KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Finished Goods (2018 - 2025)

Ionis Pharmaceuticals (IONS) has 8 years of Finished Goods data on record, last reported at $2.1 million in Q1 2025.

  • For Q1 2025, Finished Goods rose 959.0% year-over-year to $2.1 million; the TTM value through Mar 2025 reached $2.1 million, up 959.0%, while the annual FY2024 figure was $276000.0, 79.22% up from the prior year.
  • Finished Goods reached $2.1 million in Q1 2025 per IONS's latest filing, up from $276000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $2.1 million in Q1 2025 and bottomed at $63000.0 in Q3 2024.
  • Average Finished Goods over 5 years is $563294.1, with a median of $288000.0 recorded in 2022.
  • Peak YoY movement for Finished Goods: tumbled 87.02% in 2021, then skyrocketed 959.0% in 2025.
  • A 5-year view of Finished Goods shows it stood at $390000.0 in 2021, then tumbled by 57.95% to $164000.0 in 2022, then decreased by 6.1% to $154000.0 in 2023, then surged by 79.22% to $276000.0 in 2024, then surged by 667.39% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $2.1 million in Q1 2025, $276000.0 in Q4 2024, and $63000.0 in Q3 2024.